Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18634138 | 0.79 | FDPS (0.30) | — | |
| SCHEMBL14687475 | 0.78 | — | — | |
| SCHEMBL6729261 | 0.74 | TSHR (0.32) | TSHRTDP1 | |
| SCHEMBL12148168 | 0.74 | TSHR (0.32) | TSHRTDP1 | |
| SCHEMBL12424394 | 0.74 | TSHR (0.32) | TSHRTDP1 | |
| SCHEMBL349600 | 0.73 | — | — | |
| SCHEMBL224972 | 0.72 | CA1 (0.32) | TSHRTDP1 | |
| SCHEMBL6729266 | 0.72 | TSHR (0.30) | TSHRTDP1 | |
| SCHEMBL224971 | 0.72 | TSHR (0.30) | TSHRTDP1 | |
| SCHEMBL17771560 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8618103-B2 | Inhibitors of JAK | HOFFMANN-LA ROCHE INC. (US) | 2013-12-31 | — | — | US | disclosed |
| EP-2475667-A1 | INHIBITORS OF JAK | F. Hoffmann-La Roche AG (CH) | 2012-07-18 | — | — | EP | disclosed |
| WO-2011029804-A1 | INHIBITORS OF JAK | F. HOFFMANN-LA ROCHE AG (CH) | 2011-03-17 | — | — | WO | disclosed |
| US-20110059118-A1 | INHIBITORS OF JAK | DE VICENTE FIDALGO JAVIER | 2011-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110059118-A1 | INHIBITORS OF JAK | JAK1, JAK3, JAK2 | TSHR 974/4885TDP1 2588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.